NeuroOne to Present New Trigeminal Nerve Ablation System and Drug Delivery Platform at ASSFN Meeting
NeuroOne Medical Technologies will showcase its recently FDA-cleared OneRF® Trigeminal Nerve Ablation System and provide updates on its investigational SEEG-Drug Delivery System at the 2026 ASSFN Biennial Meeting, highlighting advancements in neurological surgery.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting, taking place May 30-June 2, 2026, in Cleveland, Ohio. The company will present its recently 510(k)-cleared OneRF® Trigeminal Nerve Ablation System, which received FDA clearance under K251243. This system is designed for radiofrequency lesioning to treat chronic facial pain or for functional neurosurgical procedures.
The OneRF® Trigeminal Nerve Ablation System features a multi-contact RF probe that enables precise mapping and ablation in fewer cycles without repositioning. According to the company, the system, which uses the OneRF® Generator, may reduce procedural time and improve patient comfort. NeuroOne recently completed the limited market release of this system.
In addition, NeuroOne will share details on its SEEG-Drug Delivery System, which is under development for investigational studies in humans and research in laboratory animals. The device aims to combine drug delivery, recording, and stimulation capabilities, supporting multiple trajectories and enabling repeated dosing through a single implant. The company notes that this device is not yet approved or cleared by the FDA for sale.
NeuroOne will present a scientific presentation titled "Integrating Drug Delivery Capabilities into a SEEG-Based Recording, Stimulation, and Ablation Platform Technology" on Sunday, May 31, 2026, from 3:40 PM to 6:00 PM ET. Two posters will also be presented: "SEEG-Guided Radiofrequency Ablation with Real-Time Temperature Control: From Early Clinical Experience to the Development of a Post-Market Registry" and "New FDA-cleared Multi-Contact RF Probe for Trigeminal Neuralgia: Cadaveric Feasibility and Usability Evaluation."
Multiple neurosurgeon presentations on clinical experiences with both the OneRF® Radiofrequency Ablation System (for brain) and the OneRF® Trigeminal Nerve Ablation System are also anticipated. The OneRF® Radiofrequency Ablation System (FDA clearance K231675) is indicated for creating radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
The implications of these developments are significant for patients suffering from neurological disorders. The OneRF® Trigeminal Nerve Ablation System offers a new option for treating chronic facial pain with potentially shorter procedures and improved comfort. The SEEG-Drug Delivery System, if successfully developed, could enable targeted drug delivery to the brain while recording neural activity, potentially advancing treatment for conditions such as epilepsy and movement disorders. For more information, visit nmtc1.com.